• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

    339.41 +6.41 (+1.92%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,176,555
    Open 330.81
    Bid (Size) 325.00 (120)
    Ask (Size) 345.00 (40)
    Prev. Close 333.00
    Today's Range 330.54 - 343.36
    52wk Range 225.84 - 495.55
    Shares Outstanding 118,847,693
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug... 
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup ↗
    Via Chartmill

    Performance

    YTD
    -15.2%
    -15.2%
    1 Month
    +6.4%
    +6.4%
    3 Month
    -8.5%
    -8.5%
    6 Month
    -27.0%
    -27.0%
    1 Year
    +41.4%
    +41.4%

    More News

    Read More
    News headline image
    New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
    Via MarketMinute
    Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Presents a Growth Story at a Technical Turning Point ↗
    Via Chartmill
    News headline image
    Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast TTR Investor Webinar
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally ↗
    Via Stocktwits
    Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Case Study in Affordable Growth ↗
    Via Chartmill
    Alnylam Pharmaceuticals (NASDAQ:ALNY) Fits the 'Affordable Growth' GARP Profile ↗
    Via Chartmill
    Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Fair Valuation ↗
    Via Chartmill
    News headline image
    Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Why Alnylam Pharmaceuticals Stock Was Soaring on Monday ↗
    Via The Motley Fool
    News headline image
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Why Alnylam Pharmaceuticals Stock Slipped Today ↗
    Via The Motley Fool
    News headline image
    Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Should You Buy Alnylam Pharmaceuticals Before Feb. 12? ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
    Via PredictStreet
    Topics Economy Intellectual Property Stocks
    News headline image
    Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
    Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
    What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
    The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 339.41
    When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 04/14/26 04:00 PM ET
    What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 40.34B
    How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
    Alnylam Pharmaceuticals, Inc. - Common Stock has 40B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.